Related references
Note: Only part of the references are listed.Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Benjamin M. Scirica et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiovascular Biology of the Incretin System
John R. Ussher et al.
ENDOCRINE REVIEWS (2012)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans
Annis Marney et al.
HYPERTENSION (2010)
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
Michael R. MacDonald et al.
EUROPEAN HEART JOURNAL (2008)
Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension
Edwin K. Jackson et al.
HYPERTENSION (2008)
Inflammatory mediators and the failing heart: A translational approach
A Diwan et al.
CURRENT MOLECULAR MEDICINE (2003)
Congestive heart failure in type 2 diabetes - Prevalence, incidence, and risk factors
GA Nichols et al.
DIABETES CARE (2001)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
